Skip to main content
    I

    Immunic Inc (IMUX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.10
    +0.44 (+6.61%)

    Market Cap: $90.87M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    -46.98%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.96
    Range$-2.58 - $-0.67
    11 analysts
    EPS Revisions
    1
    0
    7d
    7
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.19+19.4%
    60d ago$-1.18+18.6%
    30d ago$-0.960.0%
    7d ago$-0.960.0%
    Current$-0.96
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.48
    Range$-2.64 - $-0.01
    11 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.48---
    Sep 26EST
    		-$-0.96---
    Jun 26
    Reported Aug 11
    		$-0.80$-1.24+35.48%Beat-300.0%
    Mar 26
    Reported May 13
    		$-1.08$-0.96-12.50%Miss-332.0%
    Dec 25
    Reported Feb 26
    		$-0.12$-0.10-20.00%Miss+95.2%
    Sep 25
    Reported Nov 13
    		$-1.30$-1.77+26.55%Beat+45.8%
    Jun 25
    Reported Aug 7
    		$-0.20$-0.18-11.11%Miss+90.5%
    Mar 25
    Reported May 15
    		$-0.25$-0.25+0.00%Beat+91.7%
    Dec 24
    Reported Mar 31
    		$-2.50$-2.38-5.04%Miss-420.8%
    Sep 24
    Reported Nov 7
    		$-2.40$-2.18-10.09%Miss+52.9%
    Jun 24
    Reported Aug 8
    		$-2.10$-2.33+9.87%Beat+61.1%
    Mar 24
    Reported May 8
    		$-3.00$-2.65-13.21%Miss+48.3%
    Dec 23
    Reported Feb 22
    		$-0.48$-0.51+5.88%Beat+91.8%
    Sep 23
    Reported Nov 14
    		$-5.10$-5.07-0.59%Miss+26.1%
    Jun 23
    Reported Aug 3
    		$-5.40$-5.12-5.47%Miss+25.0%
    Mar 23
    Reported May 11
    		$-5.80$-4.80-20.83%Miss+21.6%
    Dec 22
    Reported Feb 23
    		$-5.88$-7.42+20.75%Beat-716.7%
    Sep 22
    Reported Nov 3
    		$-6.90$-6.95+0.72%Beat+9.2%
    Jun 22
    Reported Aug 4
    		$-7.20$-7.30+1.37%Beat+12.2%
    Mar 22
    Reported May 10
    		$-7.40$-7.57+2.25%Beat+9.1%
    Dec 21
    Reported Feb 24
    		$-0.72$-0.76+5.26%Beat-56.5%
    Sep 21
    Reported Nov 4
    		$-7.60$-7.52-1.06%Miss-8.6%
    Jun 21
    Reported Aug 6
    		$-8.20$-6.67-22.94%Miss+8.9%
    Mar 21
    Reported May 6
    		$-8.14$-6.85-18.83%Miss-930.4%
    Dec 20
    Reported Feb 26
    		$-0.46$-0.60+23.33%Beat+93.9%
    Sep 20
    Reported Nov 5
    		$-7.00$-6.47-8.19%Miss+14.6%
    Jun 20
    Reported Aug 2
    		$-9.00$-7.27-23.80%Miss+40.8%
    Mar 20
    Reported May 8
    		$-0.79$-0.95+16.84%Beat+12.7%
    Dec 19
    Reported Mar 16
    		$-7.50$-7.60+1.32%Beat-212.5%
    Sep 19
    Reported Nov 7
    		$-8.20$-6.50-26.15%Miss+26.8%
    Jun 19
    Reported Aug 8
    		$-15.20$-6.80-123.53%Miss-26.7%
    Mar 19
    Reported Apr 10
    		$-0.91$-0.59-53.39%Miss+93.3%
    Dec 18
    Reported Mar 4
    		$-2.40$-0.14-1614.29%Miss+82.9%
    Sep 18
    Reported Nov 7
    		$-11.20$-11.20+0.00%Beat+6.7%
    Jun 18
    Reported Aug 7
    		$-12.00$-13.20+9.09%Beat-3.4%
    Mar 18
    Reported May 8
    		$-13.60$-13.60+0.00%Beat+12.8%
    Dec 17
    Reported Mar 13
    		$-14.00$-12.40-12.90%Miss+5.4%
    Sep 17
    Reported Oct 25
    		$-12.00$-12.80+6.25%Beat-
    Jun 17
    Reported Aug 3
    		$-11.60$-14.13+17.91%Beat-
    Mar 17
    Reported May 9
    		$-15.60$-14.60-6.85%Miss-
    Dec 16
    Reported Mar 7
    		$-14.80$-14.20-4.23%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.15EV/EBITDAN/A
    Price/FCF-3.43xFCF Yield-29.17%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-138.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.05xQuick Ratio5.05x
    Trading Statistics
    Beta1.45Avg Volume460.77K
    52-Week High$17.4352-Week Low$5.06

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.58
    SMA 20$8.63
    SMA 50$12.07
    SMA 200$11.43
    EMA 10$7.68
    EMA 20$8.67
    EMA 50$10.80
    EMA 200$11.46

    MACD

    Line: -1.37Signal: -1.39Hist: 0.02

    ADX

    ADX: 46.6+DI: 13.2-DI: 36.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$8.48

    Bollinger Bands

    Upper Band$11.14
    Lower Band$6.11
    %B Position5826%(Upper)
    Band Width0.20

    RSI (14-Day)

    Oversold
    29.3

    Momentum Oscillators

    Stoch %K10.6
    Stoch %D11.6
    Williams %R-79.1
    ROC (10d)-17.8%
    Momentum-1.54
    CCI (20d)-110.2
    MFI (14d)33.0

    Volatility Measures

    ATR (14d)$0.77(10.9%)
    StdDev (20d)1.26
    Hist Vol92.2%(High)

    Volume Flow

    VWAP$6.94
    OBV22.9M
    AD Line104.3B
    CMF (20d)-0.186

    Volume Metrics

    Avg Vol (20d)466.4K
    Vol Ratio0.6x
    VWMA (20d)$8.65

    Pivot Points

    R3$7.70
    R2$7.37
    R1$7.01
    Pivot Point$6.68
    S1$6.33
    S2$6.00
    S3$5.64

    Advanced Oscillators

    TSI-48.35
    Ultimate Osc39.0
    KST-377.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$114,000$0$0$0$0$0
    Cost of Revenue$0$0$42,000$0$0$0$35,000$0$0$0$23,000$0
    Gross Profit$0$0$-42,000$0$0$0$-35,000$0$0$0$-23,000$0
    Operating Expenses$35.33M$33.23M$23.33M$25.99M$27.08M$26.82M$25.63M$25.73M$22.81M$23.88M$23.38M$23.57M
    R&D$25.93M$25.63M$19.07M$20.01M$21.37M$21.53M$21.62M$21.37M$18.32M$18.74M$19.28M$19.80M
    SG&A$9.40M$7.61M$4.26M$5.98M$5.71M$5.29M$4.01M$4.36M$4.49M$5.14M$4.10M$3.77M
    Operating Income$-35,327,000$-33,235,000$-23,327,000$-25,993,000$-27,083,000$-26,825,000$-25,631,000$-25,726,000$-22,814,000$-23,881,000$-23,381,000$-23,570,000
    Interest Income$1.29M$760,000$197,000$419,000$241,000$183,000$429,000$776,000$998,000$1.19M$541,000$766,000
    Interest Expense$0$0$0$0$0$0$0$0$0$5.70M$0$0
    Income Before Tax$-34,099,000$-32,588,000$-19,300,000$-25,579,000$-26,820,000$-25,473,000$-25,175,000$-24,368,000$-21,380,000$-29,584,000$-21,572,000$-22,769,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-34,099,000$-32,588,000$-19,300,000$-25,579,000$-26,820,000$-25,473,000$-25,175,000$-24,368,000$-21,380,000$-29,584,000$-21,572,000$-22,769,000
    EBITDA$-35,351,000$-33,315,000$-19,455,000$-25,958,000$-27,018,000$-25,613,000$-25,569,000$-25,102,000$-22,347,000$-30,745,000$-22,090,000$-23,501,000
    EBIT$-35,385,000$-33,348,000$-19,497,000$-25,998,000$-27,061,000$-25,656,000$-25,604,000$-25,144,000$-22,378,000$-30,771,000$-22,113,000$-23,535,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMUX

    News

    Immunic schedules November 12 results for Immunic stock

    Immunic has scheduled its next results date for November 12, 2026. The late-stage biotechnology company, focused on oral therapies for neurological diseases like multiple sclerosis...

    ad-hoc-news.de•10/15/26•Neutral

    B. Riley Securities Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $27

    B. Riley Securities has reiterated its Buy rating on Immunic (IMUX.US) and maintained its target price of $27. This indicates continued confidence in the company's prospects and valuation by the investment firm.

    Moomoo•10/13/26•Bullish

    Immunic Inc (10V.HM) interactive stock chart

    This page provides an interactive stock chart for Immunic Inc (10V.HM) on Yahoo Finance, showing its current trading price, daily change...

    Yahoo Finance UK•10/9/26•Neutral

    Immunic Inc (10V.HM) valuation measures and financial statistics

    This article provides detailed valuation measures and financial statistics for Immunic Inc (10V.HM). It includes market capitalization, enterprise value, various price ratios, profitability metrics...

    Yahoo Finance UK•10/8/26•Neutral

    Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

    Immunic, Inc. announced that it will present new clinical, biomarker, and preclinical data on its lead investigational asset, vidofludimus calcium (IMU-838)...

    PR Newswire•10/7/26•Bullish

    IMUX Valuation and Fair Value

    P/E
    -2.2x
    P/FCF
    -3.4x
    P/B
    2.4x
    See GNG's fair value

    IMUX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -138.2%
    FCF yield
    -29.2%

    IMUX Competitors

    CompanyTicker
    Biomea Fusion IncBMEA
    Hyperfine IncHYPR
    OnKure Therapeutics, Inc.OKUR
    Rallybio CorpRLYB
    Insight Molecular Diagnostics Inc.IMDX
    Forian IncFORA
    Anixa Biosciences IncANIX
    Equillium IncEQ

    Sector: Healthcare

    IMUX Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    0
    Buy
    12
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IMUX Bull Case vs Bear Case

    Bull case

    • 100.0% of IMUX's analyst ratings are Buy or Strong Buy.

    Bear case

    • IMUX beat EPS estimates in 25.0% of its last 8 reported quarters.

    IMUX Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    0.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.96
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    7 up, 3 down

    Frequently Asked Questions About IMUX

    Does IMUX pay dividends?

    Immunic Inc (IMUX) does not currently pay a regular dividend.

    What is IMUX's market cap?

    Immunic Inc (IMUX) has a market capitalization of $90.87M with a current stock price of $7.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In